Cargando…

Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer

Testosterone plays a significant role in maintaining the tumor microenvironment. The role of the target serum testosterone (TST) level in enzalutamide- (Enza) and abiraterone (Abi)-treated castration-resistant prostate cancer (CRPC) patients was studied. In total, 107 patients treated with Enza and/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakamoto, Shinichi, Maimaiti, Maihulan, Xu, Minhui, Kamada, Shuhei, Yamada, Yasutaka, Kitoh, Hiroki, Matsumoto, Hiroaki, Takeuchi, Nobuyoshi, Higuchi, Kosuke, Uchida, Haruhito A., Komiya, Akira, Nagata, Maki, Nakatsu, Hiroomi, Matsuyama, Hideyasu, Akakura, Koichiro, Ichikawa, Tomohiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518240/ https://www.ncbi.nlm.nih.gov/pubmed/30978937 http://dx.doi.org/10.3390/jcm8040489

Ejemplares similares

Revision of CHAARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients
por: Kanesaka, Manato, et al.
Publicado: (2021)

Treatment strategy for metastatic prostate cancer with extremely high PSA level: reconsidering the value of vintage therapy
por: Yamada, Yasutaka, et al.
Publicado: (2018)

Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
por: Rana, Dikshyanta, et al.
Publicado: (2021)

Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
por: Li, Pei-Yu, et al.
Publicado: (2022)

Prognostic Value of High-Sensitivity Modified Glasgow Prognostic Score in Castration-Resistant Prostate Cancer Patients Who Received Docetaxel
por: Ando, Keisuke, et al.
Publicado: (2021)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
por: Kawahara, Takashi, et al.
Publicado: (2023)

Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
por: Demirci, Ayşe, et al.
Publicado: (2021)

Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer
por: Tsujino, Takuya, et al.
Publicado: (2023)

Significant prognostic difference between Grade Group 4 and 5 in the 2014 International Society of Urological Pathology Grading System for High Grade Prostate Cancer with Bone Metastasis
por: Yamada, Yasutaka, et al.
Publicado: (2017)

Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
por: Cheng, Heather H., et al.
Publicado: (2015)

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
por: George, Daniel J., et al.
Publicado: (2021)

Mental health care utilization among men with castration‐resistant prostate cancer receiving abiraterone or enzalutamide
por: Tsao, Phoebe A., et al.
Publicado: (2023)

Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases
por: Schoen, Martin W., et al.
Publicado: (2022)

A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment
por: Kawahara, Takashi, et al.
Publicado: (2020)

Observational study on time on treatment with abiraterone and enzalutamide
por: Fallara, Giuseppe, et al.
Publicado: (2020)

Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis
por: Fang, Mike, et al.
Publicado: (2017)

Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer
por: Torquato, Samantha, et al.
Publicado: (2019)

Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation
por: Simon, Iris, et al.
Publicado: (2021)

The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide
por: Serrano Domingo, Juan José, et al.
Publicado: (2021)

Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
por: Tagawa, Scott T., et al.
Publicado: (2021)

Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
por: Lin, Yi-Ting, et al.
Publicado: (2021)

Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
por: Antonarakis, Emmanuel S., et al.
Publicado: (2023)

Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases
por: Schoen, Martin W., et al.
Publicado: (2023)

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation
por: Wright, Timothy C., et al.
Publicado: (2021)

Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?
por: Chen, Ming-kun, et al.
Publicado: (2022)

Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
por: Benoist, Guillemette E., et al.
Publicado: (2016)

Circulating Tumor Cell–Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
por: Chung, Jae-Seung, et al.
Publicado: (2019)

Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review
por: Zhang, Wei, et al.
Publicado: (2017)

A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Kim, Stephanie I., et al.
Publicado: (2021)

Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer
por: Alibhai, Shabbir M. H., et al.
Publicado: (2021)

Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
por: Tagawa, Scott T., et al.
Publicado: (2022)

Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland
por: Sigorski, Dawid, et al.
Publicado: (2023)

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
por: Tseng, Chi-Shin, et al.
Publicado: (2023)

Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone
por: Ramaswamy, Krishnan, et al.
Publicado: (2020)

Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer: A systematic review and meta-analysis of randomized controlled trials
por: Zheng, Xiaonan, et al.
Publicado: (2019)

Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wei, ZhenHeng, et al.
Publicado: (2021)

Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience
por: Raju, Rachel, et al.
Publicado: (2021)

Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Kim, Stephanie I., et al.
Publicado: (2021)

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial
por: Izumi, Kouji, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qr2bs8t0hsrsac47sov9sf04bd